Activities of lipogenic enzymes in subcutaneous adipose tissue are not increased in patients with chronic kidney failure.
Since renal replacement therapy has started to be a routine procedure in chronic kidney disease (CKD), patients no longer die of end-stage renal disease (ESRD). Today, patients with CKD live longer and the most important causes of morbidity and mortality in this group are cardiovascular events. Lipid abnormalities, such as hypertriglyceridemia (HT), are an important factor of high cardiovascular risk in this group. It is known that HT is partially caused by inhibition of lipolysis, but it is also postulated that increased lipogenesis is another cause of HT. Previous studies performed in our center has provided evidence that lipogenesis is increased in the animal model of ESRD. The aim of this study was to investigate the activities of lipogenic enzymes in the subcutaneous white adipose tissue in patients with CKD. The study was performed on 36 patients (17 women and 19 men). Patients with ESRD were divided into 2 groups: patients on conservative treatment in the prehemodialysis period (pre‑HD group, n = 18) and patients on maintenance hemodialysis (HD group, n = 18). The control group consisted of 22 patients without ESRD. The activities of lipogenic enzymes in the subcutaneous white adipose tissue (fatty acid synthase, adenosine triphosphate citrate lyase, malic enzyme, glucose‑6‑phosphate dehydrogenase, and 6‑phosphogluconate dehydrogenase) were assessed by spectrophotometry. There were no statistically significant differences in the activities of lipogenic enzymes in a fat tissue sample between patients with ESRD and the control group. The results did not confirm increased lipogenesis in patients with ESRD.